A Phase 2 interventional study of DOR/ISL in HIV-1 and HIV Infection, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.
Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 46th largest by planned enrollment of the 66 interventional ones that give a count, is the only one that started in 2026, is one of 25 in phase 2, and was the 75th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now.
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 163 across the 66 interventional studies, 357 across the 6 observational. Of the 66 that completed or were terminated, 29 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 75 studies in HIV Infections by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first.
Drug: DOR/ISL
Drug pages: Doravirine · Islatravir
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
Also known as: MK-8591A
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
The plasma AUC0-24 will be assessed.
Time frame: At designated timepoints on Day 28
Maximum plasma concentration (Cmax) of ISL
The plasma Cmax will be assessed.
Time frame: At designated timepoints on Day 28
Time to maximum plasma concentration (Tmax) of ISL
The plasma Tmax will be assessed.
Time frame: At designated timepoints on Day 28
Apparent plasma terminal half-life (t½) of ISL
The plasma t½ will be assessed.
Time frame: At designated timepoints on Day 28
Apparent clearance (CL/F) of ISL
The CL/F will be assessed.
Time frame: At designated timepoints on Day 28
Volume of distribution (Vz/F) of ISL
The Vz/F will be assessed.
Time frame: At designated timepoints on Day 28
Percentage of participants with ≥1 adverse event (AE) through Week 24
The percentage of participants with AE(s) will be assessed.
Time frame: Up to ~24 weeks
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
The percentage of participants discontinuing from therapy due to AE(s) will be assessed.
Time frame: Up to ~24 weeks
Percentage of participants with ≥1 AE through Week 96
The percentage of participants with AE(s) will be assessed.
Time frame: Up to 96 weeks
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
The percentage of participants with AE(s) will be assessed.
Time frame: Up to 96 weeks
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed.
Time frame: Weeks 24, 48, and 96
Percentage of VS participants with HIV-1 RNA <50 copies/mL
The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be assessed.
Time frame: Weeks 24, 48, and 96
Percentage of VS participants with HIV-1 RNA <200 copies/mL
The percentage of VS participants with HIV-1 RNA \<200 copies/mL will be assessed.
Time frame: Weeks 24, 48, and 96
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be assessed.
Time frame: Weeks 24, 48, and 96
Percentage of TN participants with HIV-1 RNA <200 copies/mL
The percentage of TN participants with HIV-1 RNA \<200 copies/mL will be assessed.
Time frame: Weeks 24, 48, and 96
Change from baseline in CD4+ T-cell counts in VS and TN participants
The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants.
Time frame: Weeks 24, 48, and 96
Percentage of participants with viral drug resistance to DOR or ISL
The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144.
Time frame: Weeks 24, 48, 96, and 144
No study locations are listed for this record.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Start is estimated for Dec 2026; primary completion for Sep 2029, 33 months later.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 33 months is above that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir